BioWorld Asia

May 21, 2003

View Archived Issues

Chiron Plans To Pay £542 Million In Cash To Acquire PowderJect

LONDON - Chiron Corp. plans to acquire PowderJect Pharmaceuticals plc in an agreed-to cash offer valuing the vaccines manufacturer at £542 million (US$878 million). (BioWorld International) Read More

EU Officials Call U.S. Complaint On GMOs 'Misguided, Unhelpful'

Read More

HIV's Vif Protein Revealed As Potential Therapeutic Target

Read More

Germany At Forefront Of Effort For International Cloning Ban

Read More

CAT Cuts Staff As Part Of Plan To Concentrate On Development

Read More

Seven Organizations Launch Alternative Splicing Project

Read More

MedPharma Postpones IPO As Markets Remain Resistant

Read More

Transgene Pushing Ahead With Targeted Development Program

Read More

Other News To Note

Read More